

# Hybrid single-photon emission computed tomography/computed tomography (SPECT-CT) imaging results in chronic low back pain patients as compared to an asymptomatic control group

|  |   |  |
|--|---|--|
| <b>Submission date</b><br>26/12/2013   | <b>Recruitment status</b><br>No longer recruiting     | <input type="checkbox"/> Prospectively registered    |
|  |   | <input type="checkbox"/> Protocol                    |
| <b>Registration date</b><br>17/02/2014 | <b>Overall study status</b><br>Completed              | <input type="checkbox"/> Statistical analysis plan   |
|  |   | <input checked="" type="checkbox"/> Results          |
| <b>Last Edited</b><br>16/01/2020       | <b>Condition category</b><br>Musculoskeletal Diseases | <input type="checkbox"/> Individual participant data |

## Plain English summary of protocol

### Background and study aims

For patients with low chronic low back pain that is not cured by conservative treatment, more invasive treatments can be considered. Those treatments may consist in injection, application of high frequency current or surgery. Success is dependent on how precisely the painful structure is identified. The new molecular imaging modality SPECT-CT detects increased bone metabolism during the degeneration process. It might be helpful in identifying the chronic low back pain phenotype. We want to evaluate the sensitivity of this molecular imaging modality in a group of patients suffering from chronic low back pain, as compared to a control group with no chronic back pain.

### Who can participate?

Patients older than 18 years with chronic (> 3 months) low back pain without a specific pain phenotype on MRI, CT and classical X-Ray are referred for SPECT-CT imaging. In the control group, the patients were referred for SPECT-CT for other reasons than chronic low back pain.

### What does the study involve?

Patients are asked if they consent to the analysis of their data. All patients undergo a SPECT-CT as planned within the diagnostic process for their condition.

### What are the possible benefits and risks of participating?

This study is about data analysis only and there are no benefits or additional risks in participating. On rare occasions patients may be allergic to the product that is injected for imaging.

### Where is the study run from?

AZ Nikolaas Hospital, Sint Niklaas, Belgium.

When is the study starting and how long is it expected to run for?  
August 2013 to January 2014.

Who is funding the study

The SPECT-CT is part of the normal diagnostic process and is paid for by the standard procedure (health insurance). Costs for data recording and analysis are covered by the investigator.

Who is the main contact?

Dr Erik Van de Kelft, Director of the Neurosurgery Department, erik.vandekelft@aznikolaas.be

Dr Koen Melis, Director of the Neuroradiology Department, koen.melis@aznikolaas.be

## Contact information

### Type(s)

Scientific

### Contact name

Dr Erik Van de Kelft

### Contact details

Moerlandstraat, 1

Sint Niklaas

Belgium

9100

+32 (0)3 760 21 72

erik.vandekelft@aznikolaas.be

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

2013-06/02

## Study information

### Scientific Title

Evaluation of the prevalence of increased Phosphorus uptake at lumbar level during SPECT-CT in a group of patients with low back pain as compared to an asymptomatic a control group

### Study objectives

SPECT-CT shows hotspots at places with an increased phosphate metabolism due to mechanical stress. This is indicative for increased bone metabolism as result of the degeneration process. We hypothesize that the prevalence of hotspots observed during SPECT-CT will be higher in the group of patients with chronic low back pain as compared to an asymptomatic control group.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Medical Ethics Committee of AZ Nikolaas, Sint Niklaas Belgium, Ref: EC 13022

**Study design**

Prospective comparative study

**Primary study design**

Observational

**Secondary study design**

Other

**Study setting(s)**

Hospital

**Study type(s)**

Diagnostic

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Sensitivity of SPECT-CT in the identification of the pain phenotype when analyzing chronic low back pain

**Interventions**

Patients with chronic low back pain (more than 3 months) are referred for SPECT-CT imaging. In the control group, the patients were referred for SPECT-CT for other reasons than chronic low back pain.

All patients undergo a SPECT-CT as planned within the diagnostic process for their condition. The imaging data will be analyzed.

**Intervention Type**

Procedure/Surgery

**Primary outcome measure**

Number of patients with hotspots on SPECT-CT in the group with chronic low back pain, compared to the number of patients with hotspots on SPECT-CT in the group without chronic low back pain.

**Secondary outcome measures**

Analysis of the structures that show activity in both groups. The SPECT-CT images are read by the neuroradiologist immediately after the investigation. As the value of SPECT-CT as diagnostic tool for spinal pain is measured the interpretation of the images is done only once.

**Overall study start date**

08/08/2013

**Completion date**

30/01/2014

## Eligibility

**Key inclusion criteria**

1. Patients older than 18 years
2. Referred to the department of medical imaging for SPECT-CT
3. Having signed the informed consent

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

200

**Total final enrolment**

200

**Key exclusion criteria**

1. Recent vertebral fractures
2. History of lumbar spine surgery
3. Diagnosed malignancy
4. Pregnancy
5. Contraindication for injection 99mTc hydroxymethane diphosphonate (99mTc-HDP)

**Date of first enrolment**

08/08/2013

**Date of final enrolment**

30/01/2014

## Locations

**Countries of recruitment**

Belgium

**Study participating centre**  
**Moerlandstraat, 1**  
Sint Niklaas  
Belgium  
9100

## **Sponsor information**

**Organisation**  
AZ Nikolaas

**Sponsor details**  
c/o Van de Kelft Erik  
AZ Nikolaas  
Moerlandstraat 1  
Sint Niklaas  
Belgium  
9100  
+32 (0)3 760 21 72  
erik.vandekelft@aznikolaas.be

**Sponsor type**  
Hospital/treatment centre

**Website**  
<http://www.neuro-chirurgie.org/BENL/site/index.aspx>

## **Funder(s)**

**Funder type**  
Industry

**Funder Name**  
Neuro-surgery.org (Belgium)

**Funder Name**  
The investigation (SPECT-CT) is part of the normal diagnostic process for the patients, thus the costs involved are carried by the patients individual health insurance.

## **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | results | 01/10/2017   | 16/01/2020 | Yes            | No              |